[go: up one dir, main page]

WO1999011763A3 - Procede de purification et de concentration d'aav-2 et de ses fractions antigenes - Google Patents

Procede de purification et de concentration d'aav-2 et de ses fractions antigenes Download PDF

Info

Publication number
WO1999011763A3
WO1999011763A3 PCT/DE1998/002569 DE9802569W WO9911763A3 WO 1999011763 A3 WO1999011763 A3 WO 1999011763A3 DE 9802569 W DE9802569 W DE 9802569W WO 9911763 A3 WO9911763 A3 WO 9911763A3
Authority
WO
WIPO (PCT)
Prior art keywords
aav
purifying
antigen portions
concentrating
antigen
Prior art date
Application number
PCT/DE1998/002569
Other languages
German (de)
English (en)
Other versions
WO1999011763A2 (fr
WO1999011763A9 (fr
Inventor
Juergen Kleinschmidt
Andrea Kern
Original Assignee
Deutsches Krebsforsch
Juergen Kleinschmidt
Andrea Kern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch, Juergen Kleinschmidt, Andrea Kern filed Critical Deutsches Krebsforsch
Priority to EP98951251A priority Critical patent/EP1009809A2/fr
Publication of WO1999011763A2 publication Critical patent/WO1999011763A2/fr
Publication of WO1999011763A3 publication Critical patent/WO1999011763A3/fr
Publication of WO1999011763A9 publication Critical patent/WO1999011763A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé de purification et de concentration d'AAV-2 et de ses fractions antigènes, consistant à lier l'AAV-2 ou ses fractions antigènes à un matériau chromatographique activé renfermant des anticorps accouplés dirigés contre l'AVV-2, et à effectuer ensuite l'élution avec une solution renfermant 0,5 à 4,5 M de MgCl2. L'invention concerne en outre un nécessaire pour la mise en oeuvre de ce procédé.
PCT/DE1998/002569 1997-09-02 1998-09-01 Procede de purification et de concentration d'aav-2 et de ses fractions antigenes WO1999011763A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP98951251A EP1009809A2 (fr) 1997-09-02 1998-09-01 Procede de purification et de concentration d'aav-2 et de ses fractions antigenes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1997138292 DE19738292C1 (de) 1997-09-02 1997-09-02 Verfahren zur Reinigung und Konzentrierung von AAV-2 sowie antigenen Teilen davon
DE19738292.4 1997-09-02

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09508037 A-371-Of-International 2000-06-23
US09/886,144 Continuation US20010031463A1 (en) 1997-09-02 2001-06-20 Method for purifying and concentrating AAV-2 and antigen portions thereof

Publications (3)

Publication Number Publication Date
WO1999011763A2 WO1999011763A2 (fr) 1999-03-11
WO1999011763A3 true WO1999011763A3 (fr) 1999-05-14
WO1999011763A9 WO1999011763A9 (fr) 1999-06-17

Family

ID=7840939

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1998/002569 WO1999011763A2 (fr) 1997-09-02 1998-09-01 Procede de purification et de concentration d'aav-2 et de ses fractions antigenes

Country Status (3)

Country Link
EP (1) EP1009809A2 (fr)
DE (1) DE19738292C1 (fr)
WO (1) WO1999011763A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011997A1 (fr) * 1993-10-28 1995-05-04 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Virus adeno-associe et son utilisation pour diagnostiquer un avortement precoce
WO1997008298A1 (fr) * 1995-08-30 1997-03-06 Genzyme Corporation Purification d'adenovirus et de virus adeno-associe (aav) par voie chromatographique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011997A1 (fr) * 1993-10-28 1995-05-04 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Virus adeno-associe et son utilisation pour diagnostiquer un avortement precoce
WO1997008298A1 (fr) * 1995-08-30 1997-03-06 Genzyme Corporation Purification d'adenovirus et de virus adeno-associe (aav) par voie chromatographique

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
D. GRIMM ET AL.: "Novel tools for production and purification of recombinant adenoassociated virus vectors.", HUMAN GENE THERAPY, vol. 9, no. 18, 10 December 1998 (1998-12-10), New York, NY, VSA, pages 2745 - 2760, XP002093963 *
K. DURKEE ET AL.: "Immunoaffinity chromatographic purification of Russell's viper venom Factor X activator using elution in high concentrations of magnesium chloride.", PROTEIN EXPRESSION AND PURIFICATION, vol. 4, no. 5, October 1993 (1993-10-01), pages 405 - 411, XP002093962 *
M. HESSING ET AL.: "Purification and quantification of recombinant Epstein-Barr viral glycoproteins gp350/220 from Chinese hamster ovary cells.", JOURNAL OF CHROMATOGRAPHY, vol. 599, no. 1-2, 22 May 1992 (1992-05-22), Amsterdam, Niederlande, pages 267 - 272, XP002093960 *
P. O'NEIL ET AL.: "Virus harvesting and affinity-based liquid chromatography.", BIO/TECHNOLOGY, vol. 11, no. 2, February 1993 (1993-02-01), Basingstoke, Grossbritannien, pages 173 - 178, XP000195205 *
T. SUGIURA ET AL.: "Purification of equine infectious anemia virus antigen by affinity chromatography.", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 5, no. 6, June 1977 (1977-06-01), Washington, DC, VSA, pages 635 - 639, XP002093961 *

Also Published As

Publication number Publication date
DE19738292C1 (de) 1999-05-12
WO1999011763A2 (fr) 1999-03-11
EP1009809A2 (fr) 2000-06-21
WO1999011763A9 (fr) 1999-06-17

Similar Documents

Publication Publication Date Title
AU5752696A (en) Dna binding antibodies
AU642403B2 (en) Method for the use and synthesis of peptides
WO1995018826A3 (fr) Antigenes a ctla-8 de primates purifiee et reactifs correspondants
AU4992997A (en) Humanized anti-cd11a antibodies
AU1432195A (en) Process for generating specific antibodies
AU3811495A (en) Antibodies
CA2220447A1 (fr) Nouveaux procedes de recuperation et de purification de proteines de fusion
AU8432498A (en) Human-cd28 specific monoclonal antibodies for antigen non-specific activation oft-lymphocytes
CA2289665A1 (fr) Recuperation de proteine par chromatographie suivie d'une filtration sur une couche chargee
AUPN999096A0 (en) Peptides, antibodies, vaccines & uses thereof
AU2002349344A1 (en) Microfluidic extraction method
AU2645297A (en) Hepatitis b monoclonal antibodies
ZA987913B (en) Fractionation of hemicellulosic materials.
AU4583397A (en) Assay for the detection of antibodies against p53
AU4375493A (en) Isolated protein receptors, antibodies which bind thereto, nucleic acid sequence coding therefor, and uses thereof
WO2001046686A3 (fr) Materiau chromatographique et procedes d'utilisation d'un tel materiau
AU2547995A (en) Monoclonal antibody specific for vascular endothelial cell antigen endoglyx-1, the antigen itself, and uses thereof
WO1999011763A3 (fr) Procede de purification et de concentration d'aav-2 et de ses fractions antigenes
AU1183195A (en) Methods for the separation of biological materials
AU4159697A (en) Interaction trap assay, reagents and uses thereof
AU1457992A (en) Pcr generated dicistronic dna molecules for producing antibodies
AU9109998A (en) High affinity immunoglobulin e receptor-like protein
AU6390696A (en) Hypoxia-responsive adhesion molecules, specific antibodies, nd their uses
AU2041095A (en) Separation-fee specific binding assays using anti-inhibitor antibodies
WO1997035015A3 (fr) Proteine apparentee a la tyrosine-phosphatase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGE 3/3, DRAWINGS, REPLACED BY A NEW PAGE 3/3; AFTER RECTIFICATION OF OBVIOUS ERRORS AS AUTHORIZEDBY THE INTERNATIONAL SEARCHING AUTHORITY

WWE Wipo information: entry into national phase

Ref document number: 1998951251

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998951251

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09508037

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1998951251

Country of ref document: EP